<VariationArchive RecordType="classified" VariationID="583952" VariationName="NC_000017.11:g.(?_61683286)_(61716073_?)del" VariationType="Deletion" Accession="VCV000583952" Version="3" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-12-11" DateCreated="2020-04-09" MostRecentSubmission="2020-04-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="570822" VariationID="583952">
      <GeneList>
        <Gene Symbol="BRIP1" FullName="BRCA1 interacting helicase 1" GeneID="83990" HGNC_ID="HGNC:20473" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17q23.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="61679139" stop="61863528" display_start="61679139" display_stop="61863528" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="59756546" stop="59940919" display_start="59756546" display_stop="59940919" Strand="-" />
          </Location>
          <OMIM>605882</OMIM>
          <Haploinsufficiency last_evaluated="2019-02-15" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRIP1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2019-02-15" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRIP1">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000017.11:g.(?_61683286)_(61716073_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17q23.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" innerStart="61683286" innerStop="61716073" display_start="61683286" display_stop="61716073" variantLength="32788" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" innerStart="59760647" innerStop="59793434" display_start="59760647" display_stop="59793434" variantLength="32788" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.(?_61683286)_(61716073_?)del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.(?_61683286)_(61716073_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.(?_59760647)_(59793434_?)del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.(?_59760647)_(59793434_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000017.11:g.(?_61683286)_(61716073_?)del AND multiple conditions" Accession="RCV000708182" Version="3">
        <ClassifiedConditionList TraitSetID="11663">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1836860">Fanconi anemia complementation group J</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-06-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-06-10" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-09" MostRecentSubmission="2020-04-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11301010</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">14576433</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18628483</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19099189</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20159562</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21127055</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21345144</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26921362</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28423363</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="11663" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
            <Trait ID="1798" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group J</ElementValue>
                <XRef ID="MONDO:0012187" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FANCJ</ElementValue>
                <XRef Type="MIM" ID="609054" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301753</ID>
                <ID Source="BookShelf">NBK5192</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management, 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/images/uploads/other/Fanconi_Anemia_Clinical_Care_Guidelines_5thEdition_web.pdf</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C1836860" DB="MedGen" />
              <XRef ID="MONDO:0012187" DB="MONDO" />
              <XRef Type="MIM" ID="609054" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1609317" SubmissionDate="2020-02-06" DateLastUpdated="2020-04-09" DateCreated="2018-10-10">
        <ClinVarSubmissionID localKey="4246123|MedGen:C0346153;C1836860" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000837292" DateUpdated="2020-04-09" DateCreated="2018-10-10" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-06-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21345144</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28423363</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11301010</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18628483</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26921362</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19099189</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21127055</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">14576433</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20159562</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exons 17-20 (also known as exons 16-19) of the BRIP1 gene. The 5' boundary is likely confined to intron 16. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. This variant has not been reported in the literature in individuals with BRIP1-related disease. This truncation affects the TopBP1-binding region (residues 1130-1153), the BCRA1 interacting region (residues 888-1063) including the phospho-S-X-X-F motif (residues 990-993) of the BRIP1 protein. The TopBP1-BRIP1 interaction plays a critical role on RPA chromatin loading following DNA replication stress and the subsequent activation of the replication checkpoint in response to DNA damage (PMID: 20159562, 21127055). The BRCA1 interacting region and phospho-S-X-X-F motif are required for BRCA1 binding (PMID: 21345144, 19099189, 11301010, 14576433) A different truncation (p.Lys998Glufs*60) that lies downstream of this variant has been determined to be pathogenic (PMID: 26921362, 18628483, 28423363, Invitae). This suggests that deletion of this region of the BRIP1 protein is causative of disease. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRIP1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.(?_59760647)_(59793434_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Hereditary Breast Carcinoma</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0346153" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Fanconi anemia, complementation group J</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C1836860" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB6933794</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1609317" TraitType="Disease" MappingType="Name" MappingValue="Hereditary Breast Carcinoma" MappingRef="Preferred">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1609317" TraitType="Disease" MappingType="Name" MappingValue="Fanconi anemia, complementation group J" MappingRef="Preferred">
        <MedGen CUI="C1836860" Name="Fanconi anemia complementation group J" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

